Advent Life Sciences

1-2 of 2 Articles
Clock icon 2 minutes

Amphista Therapeutics, a University of Dundee spin-out, has announced a multi-million-pound deal to develop first-in-class cancer therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease-causing proteins. The spin-out has announced the cl

Clock icon 2 minutes

Pheno Therapeutics, a new drug-discovery spin-out from the University of Edinburgh, has been launched with the backing of Series A funding totalling £5 million from Advent Life Sciences, the Scottish Investment Bank and LifeArc. With the £5m funding spanning over its first three years, P

1-2 of 2 Articles